Technical Analysis for IMUX - Immunic, Inc.

Grade Last Price % Change Price Change
F 14.5951 1.64% 0.24
IMUX closed up 1.99 percent on Thursday, April 22, 2021, on 32 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical IMUX trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness 1.64%
Slingshot Bearish Bearish Swing Setup 3.66%
Bullish Engulfing Bullish 3.66%
Lower Bollinger Band Walk Weakness 3.66%
Lower Bollinger Band Touch Weakness 3.66%
Oversold Stochastic Weakness 3.66%
Lower Bollinger Band Walk Weakness 13.05%
Stochastic Reached Oversold Weakness 13.05%
Below Lower BB Weakness 13.05%
Down 3 Days in a Row Weakness 13.05%
Older End-of-Day Signals for IMUX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 20 DMA 29 minutes ago
20 DMA Resistance about 1 hour ago
Up 2% about 1 hour ago
Rose Above Previous Day's High about 1 hour ago
Up 1% about 1 hour ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immunic, Inc. Description

Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Clinical Development Immunotherapy Autoimmune Diseases Autoimmune Disease Multiple Sclerosis Psoriasis Metabolism Ulcer Colitis Ulcerative Colitis Abdominal Pain Crohn's Disease Inflammatory And Autoimmune Diseases Molecule Product Primary Sclerosing Cholangitis Relapsing Remitting Multiple Sclerosis Mayo Clinic

Is IMUX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.84
52 Week Low 7.5
Average Volume 243,662
200-Day Moving Average 17.01
50-Day Moving Average 15.95
20-Day Moving Average 14.70
10-Day Moving Average 14.25
Average True Range 1.09
ADX 9.23
+DI 22.18
-DI 24.63
Chandelier Exit (Long, 3 ATRs ) 13.71
Chandelier Exit (Short, 3 ATRs ) 15.78
Upper Bollinger Band 16.40
Lower Bollinger Band 13.01
Percent B (%b) 0.4
BandWidth 23.01
MACD Line -0.51
MACD Signal Line -0.47
MACD Histogram -0.0352
Fundamentals Value
Market Cap 297.51 Million
Num Shares 20.7 Million
EPS -11.31
Price-to-Earnings (P/E) Ratio -1.27
Price-to-Sales 0.00
Price-to-Book 2.21
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.90
Resistance 3 (R3) 15.81 15.20 15.64
Resistance 2 (R2) 15.20 14.81 15.25 15.56
Resistance 1 (R1) 14.78 14.56 14.99 14.87 15.47
Pivot Point 14.17 14.17 14.28 14.22 14.17
Support 1 (S1) 13.75 13.78 13.96 13.85 13.25
Support 2 (S2) 13.14 13.54 13.19 13.16
Support 3 (S3) 12.72 13.14 13.08
Support 4 (S4) 12.82